Progressing the first Radio-DARPin Therapeutic MP0712 (212Pb x DLL3) for SCLC into the clinic ➢New patient imaging and dosimetry data ➢Update on Phase 1/2a study Patrick Amstutz, CEO Webcast call following TWC 2026 presentation February 2, 2026 Disclaimer This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of ...